XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent event
 6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent event

13. Subsequent Event

On August 4, 2023, the Company acquired Pionyr Immunotherapeutics, Inc., (“Pionyr”), a privately-held company headquartered in San Francisco, California, in accordance with the terms of the Agreement and Plan of Merger, dated August 4, 2023 (the “Merger Agreement”). Under the terms of the Merger Agreement, at the closing of the Merger, the Company acquired all of Pionyr’s assets, including approximately $43 million in net cash at the time of closing, and the Company issued the holders of Pionyr common stock a total of 1,800,652 shares of the Company’s common stock, comprised of both voting and non-voting common stock, at the purchase price of $7.15 per share and 4,153,439 shares of Series A Preferred Stock (as defined in the Merger Agreement), also at the purchase price of $7.15 per share, each share of which is convertible into one (1) share of the Company’s common stock, subject to certain conditions. The Company is in process of evaluating the accounting treatment of the transaction.